

Soft Tissue Sarcoma

CHI Formulary Treatment algorithm

Treatment algorithm- February
2024

Supporting treatment algorithms
for the clinical management of Soft
Tissue Sarcoma

Figure 1 outlines the Regimens appropriate for General Soft Tissue Sarcoma aimed at addressing the different lines of treatment after thorough review of medical and economic evidence by CHI committees.

For further evidence, please refer to CHI **Soft Tissue Sarcoma** full report. You can stay updated on the upcoming changes to our formulary by visiting our website at <https://chi.gov.sa/AboutCCHI/CCHIprograms/Pages/IDF.aspx>

Our treatment algorithm offers a robust framework for enhancing patient care and optimizing treatment outcomes across a range of treatment options, holding great promise for improving healthcare delivery.




Figure 1. Regimens appropriate for General Soft Tissue Sarcoma

fRegimens appropriate for pleomorphic RMS. **h**Not intended for neoadjuvant or adjuvant therapy of nonmetastatic disease. Not recommended for angiosarcoma or pleomorphic RMS.

iNot intended for adjuvant therapy of nonmetastatic disease. **j**Recommended only for palliative

- NCCN Guidelines Version 3.2023 Soft Tissue Sarcoma. For the level of evidence and details on the figures in the algorithm, please refer to the full report.

therapy. **k**For non-adipocytic sarcoma. **m**For the treatment of unresectable or metastatic MSI-H or dMMR solid tumors as determined by an FDA-approved test.

- NCCN Guidelines Version 3.2023 Soft Tissue Sarcoma. For the level of evidence and details on the figures in the algorithm, please refer to the full report.